diethyl aniline

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: diethyl aniline
• 英文别名: Aniline;butane
• 化学式: C₄H₁₀*C₆H₇N
• 分子量: 151.252
• InChiKey: DGPYPAWWRMCWBD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.08
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  diethyl aniline 、 2,4-喹唑啉二酮 以 三氯氧磷 为溶剂， 生成 2,4-二氯喹唑啉
  参考文献：
  名称：

  2-Aryl-4-(1-[4-heteroaryl]piperazin-1-yl)methylimidazoles: dopamine .

  摘要：

  本发明涉及下列化合物：##STR1##或其药学上可接受的酸加成盐，其中：R.sub.a代表##STR2##其中X、Y和Z相同或不同，分别代表CH或氮；R.sub.1、R.sub.2、R.sub.3和R.sub.4分别独立地代表有机或无机基团；而R.sub.5是氢、C.sub.1-C.sub.6烷基或卤素。这些化合物对于治疗和/或预防神经心理障碍具有用处，包括但不限于精神分裂症、狂躁症、痴呆、抑郁症、焦虑症、强迫行为、物质滥用、帕金森样运动障碍以及与神经阻滞剂使用有关的运动障碍。

  公开号：

  US06166205A1

文献信息

• Phthalazine derivatives and remedies for erectile dysfunction
  申请人：Eisai Co., Ltd.

  公开号：US06498159B1

  公开（公告）日：2002-12-24

  The present invention provides a phthalazine compound as a therapeutic agent for erectile dysfunction represented by the following formula, a pharmacologically acceptable salt thereof or a hydrate thereof: wherein R1 and R2 are the same as or different from each other and represent a halogen atom, a C1 to C4 alkyl group which may be substituted with a halogen atom, a C1 to C4 alkoxy group which may be substituted with a halogen atom or a cyano group; X represents a cyano group, a nitro group, a halogen atom, a hydroxyimino group which may be substituted or a heteroaryl group which may be substituted; Y represents a heteroaryl group, an aryl group which may be substituted, an alkynyl group which may substituted, an alkenyl group, an alkyl group, an optionally substituted saturated or unsaturated 4- to 8-membered amine ring, and the cyclic amine compound is a monocyclic compound, bicyclic compound or a spiro compound; l is an integer of 1 to 3; provided that the case where l is 1 or 2, X is a cyano group, a nitro group or a chlorine atom, R1 is a chlorine atom, R2 is a methoxy group and Y is a 5- or 6-membered amine ring substituted with a hydroxyl group is excluded.

  本发明提供了一种邻苯二氮杂环化合物，作为下式所代表的勃起功能障碍的治疗剂，其药理学上可接受的盐或水合物： 其中R1和R2相同或不同，分别代表卤素原子、可能被卤素原子取代的C1到C4烷基、可能被卤素原子取代的C1到C4烷氧基或氰基；X代表氰基、硝基、卤素原子、可能被取代的羟基亚胺基团或可能被取代的杂芳基团；Y代表杂芳基团、可能被取代的芳基团、可能被取代的炔基团、烯基团、烷基团、可选择地取代的饱和或不饱和的4-至8-成员氨基环，且环状胺化合物是单环化合物、双环化合物或螺环化合物；l为1到3的整数；但在l为1或2的情况下，X为氰基、硝基或氯原子，R1为氯原子，R2为甲氧基团，Y为取代羟基的5-或6-成员氨基环的情况除外。
• Novel triazine compounds useful as sorbitol dehydrogenase inhibitors
  申请人：——

  公开号：US20030004166A1

  公开（公告）日：2003-01-02

  This invention is directed to sorbitol dehydrogenase inhibitory compounds of formula I 1 wherein R 1 , R 2 and R 3 are as defined in the specification. This invention is also directed to pharmaceutical compositions containing these compounds which inhibit sorbitol dehydrogenase and to methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy, diabetic cardiomyopathy and foot ulcers, by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of the present invention with a second pharmaceutical agent, including an aldose reductase inhibitor, a sodium hydrogen ion exchange (NHE-1) inhibitor, a glycogen phosphorylase inhibitor (GPI), a selective serotonin reuptake inhibitor, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, an angiotensin converting enzyme inhibitor, a thiazolidinedione antidiabetic agent, an angiotensin 11 receptor antagonist, a &ggr;-aminobutyric acid (GABA) agonist, a phosphodiesterase type 5 inhibitor, an adenosine agonist, and a CETP inhibitor and to methods of using these combination compositions.

  这项发明涉及到化合物的抑制山梨醇脱氢酶的公式I1，其中R1、R2和R3如规范中所定义。这项发明还涉及含有这些化合物的药物组合物，其抑制山梨醇脱氢酶，并通过向患有糖尿病且因此有发生这些并发症风险的哺乳动物施用这些化合物的方法来治疗或预防糖尿病并发症，特别是糖尿病神经病变、糖尿病肾病、糖尿病微血管病、糖尿病大血管病、糖尿病心肌病和足部溃疡。这项发明还涉及含有本发明公式I的化合物与第二药物剂的组合的药物组合物，包括醛糖还原酶抑制剂、钠氢离子交换（NHE-1）抑制剂、糖原磷酸化酶抑制剂（GPI）、选择性5-羟色胺再摄取抑制剂、3-羟基-3-甲基戊二酸辅酶A还原酶抑制剂、血管紧张素转换酶抑制剂、噻唑烷二酮抗糖尿病药物、血管紧张素II受体拮抗剂、γ-氨基丁酸（GABA）激动剂、磷酸二酯酶5抑制剂、腺苷激动剂和CETP抑制剂，以及使用这些组合组合物的方法。
• Process for preparation of penicillin and cephalosporin imino halides
  申请人：Eli Lilly and Company

  公开号：US04211702A1

  公开（公告）日：1980-07-08

  Penicillin and cephalosporin imino halides are prepared by reacting of 6-acylaminopenicillins or 7-acylamino cephalosporins with a novel chlorinating compound derived from a triaryl phosphite and chlorine or bromine. The imino halide products are intermediates in the preparation of antibiotic compounds.

  青霉素和头孢菌素亚胺卤化物是通过将6-酰胺基青霉素或7-酰胺基头孢菌素与从三芳基膦酸酯和氯或溴衍生的新型氯化化合物反应制备的。亚胺卤化物产品是抗生素化合物制备过程中的中间体。
• 2,4,5,6-Tetrasubstituted pyrimidines and salts thereof
  申请人：Boehringer Ingelheim GmbH

  公开号：US03975384A1

  公开（公告）日：1976-08-17

  Compounds of the formula ##SPC1## Wherein R.sub.1 is alkoxy of 1 to 3 carbon atoms, morpholino, thiomorpholino, 1-oxido-thiomorpholino, 1,1-dioxido-thiomorpholino, or ##EQU1## where A is hydrogen, alkanoyl of 1 to 4 carbon atoms, alkenoyl of 2 to 4 carbon atoms, methoxy-(alkanoyl of 1 to 4 carbon atoms), carboxyl-(alkanoyl of 1 to 4 carbon atoms), acetyl-(alkanoyl of 1 to 4 carbon atoms), methoxy-(alkenoyl of 2 to 4 carbon atoms), carboxyl-(alkenoyl of 2 to 4 carbon atoms), acetyl-(alkenoyl of 2 to 4 carbon atoms), aminocarbonyl, mono(alkyl of 1 to 4 carbon atoms)-aminocarbonyl, di-(alkyl of 1 to 4 carbon atoms)-aminocarbonyl, methoxymethylaminocarbonyl, pyridinoyl, salicyloyl, furanoyl, or (alkyl of 1 to 3 carbon atoms)-sulfonyl, R.sub.2 is morpholino, thiomorpholino, 1-oxido-thiomorpholino, 1,1-dioxido-thiomorpholino, piperazino or N'-[acetyl-(alkanoyl of 1 to 3 arbon atoms)]-piperazino, R.sub.3 is hydrogen, chlorine, bromine, nitro, cyano, formyl, acetyl or carbalkoxy of 2 to 4 carbon atoms, and R.sub.4 is hydrogen, chlorine, bromine, cyano, carbalkoxy of 2 to 4 carbon atoms, alkyl of 1 to 6 carbon atoms, mono(carbalkoxy of 2 to 4 carbon atoms)-alkyl of 1 to 6 carbon atoms, di(carbalkoxy of 2 to 4 carbon atoms)-alkyl of 1 to 6 carbon atoms, hydroxyl, allyloxy, alkoxy of 1 to 6 carbon atoms, mercapto, allylmercapto, (alkyl of 1 to 6 carbon atoms)-mercapto, 1-oxidothiomorpholino, or --NHB where B is hydrogen, alkyl of 1 to 3 carbon atoms, cyclohexyl, phenyl, chloro-phenyl, carboxy-phenyl, carbomethoxy-phenyl or pyridyl, And non-toxic, pharmacologically acceptable acid addition salts thereof; the compounds as well as the salts are useful as antithrombotics.

  化合物的公式为##SPC1##其中R.sub.1是1到3个碳原子的烷氧基，吗啡基，硫环氧基，1-氧代硫环氧基，1,1-二氧代硫环氧基或##EQU1##其中A是氢，1到4个碳原子的烷酰基，2到4个碳原子的烯酰基，甲氧基-(1到4个碳原子的烷酰基)，羧基-(1到4个碳原子的烷酰基)，乙酰基-(1到4个碳原子的烷酰基)，甲氧基-(2到4个碳原子的烯酰基)，羧基-(2到4个碳原子的烯酰基)，乙酰基-(2到4个碳原子的烯酰基)，氨基甲酰基，单(1到4个碳原子的烷基)-氨基甲酰基，双(1到4个碳原子的烷基)-氨基甲酰基，甲氧基甲基氨基甲酰基，吡啶酰基，水杨酰基，呋喃酰基或(1到3个碳原子的烷基)-磺酰基，R.sub.2是吗啡基，硫环氧基，1-氧代硫环氧基，1,1-二氧代硫环氧基，哌嗪基或N'-[乙酰-(1到3个碳原子的烷酰基)]-哌嗪基，R.sub.3是氢，氯，溴，硝基，氰基，甲酰基，乙酰基或2到4个碳原子的羧基烷氧基，R.sub.4是氢，氯，溴，氰基，2到4个碳原子的羧基烷氧基，1到6个碳原子的烷基，单(2到4个碳原子的羧基烷氧基)-1到6个碳原子的烷基，双(2到4个碳原子的羧基烷氧基)-1到6个碳原子的烷基，羟基，丙烯氧基，1到6个碳原子的烷氧基，硫醇基，丙烯硫醇基，(1到6个碳原子的烷基)-硫醇基，1-氧代硫环氧基或--NHB，其中B是氢，1到3个碳原子的烷基，环己基，苯基，氯苯基，羧基苯基，甲氧基苯基或吡啶基，以及其无毒、药理学上可接受的酸盐；这些化合物和盐作为抗血栓剂具有用处。
• 2-Aryl-4-(1-[4-heteroaryl]piperazin-1-yl)methylimidazoles: dopamine .
  申请人：Neurogen Corporation

  公开号：US06166205A1

  公开（公告）日：2000-12-26

  Disclosed are compounds of the formula: ##STR1## or the pharmaceutically acceptable acid addition salts thereof wherein: R.sub.a represents ##STR2## where X, Y and Z are the same or different and represent CH or nitrogen; R.sub.1 R.sub.2, R.sub.3 and R.sub.4 independently represent organic or inorganic groups; and R.sub.5 is hydrogen, C.sub.1 -C.sub.6 alkyl or halogen, which compounds are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depression, anxiety, compulsive behavior, substance abuse, Parkinson-like motor disorders and motion disorders related to the use of neuroleptic agents.

  本发明涉及下列化合物：##STR1##或其药学上可接受的酸加成盐，其中：R.sub.a代表##STR2##其中X、Y和Z相同或不同，分别代表CH或氮；R.sub.1、R.sub.2、R.sub.3和R.sub.4分别独立地代表有机或无机基团；而R.sub.5是氢、C.sub.1-C.sub.6烷基或卤素。这些化合物对于治疗和/或预防神经心理障碍具有用处，包括但不限于精神分裂症、狂躁症、痴呆、抑郁症、焦虑症、强迫行为、物质滥用、帕金森样运动障碍以及与神经阻滞剂使用有关的运动障碍。